M & A: Sell Side

Today, virtual deal rooms have moved the due diligence process online, leaving physical paper-based data rooms to be a relic of the past, yet the market-leading virtual deal room providers offer only clunky and cumbersome solutions. How can you assure that your next deal runs more quickly and smoothly?
ShareVault provides the ideal web-based platform to accelerate the due diligence process associated with sell-side M&A. Control the distribution of documents for deal marketing (pre-termsheet), due diligence (post-termsheet), closing and post-merger integration.
ShareVault is the most modern, easiest-to-use, fastest and most robust virtual deal room, with the following capabilities to accelerate your next deal:
- Per-user and per-document access control settings so you can control who can see what information and when,
- Policy-based rights management so you can specify who has the right to view, print or save each document. Apply watermarks, block screenshots, prevent copy/paste, and in the event that a deal goes sour, you can even retroactively revoke the rights to open PDFs that have already been downloaded,
- Entirely web-based application does not require installation of any proprietary document viewing software,
- Instant full-text search, so that participants can quickly find the information they need, greatly compressing the due diligence timeline,
- Fast, easy-to-use tools to setup and modify the structure of the data room so your deal can proceed quickly,
- Drag-and-drop document uploader based on a fast and secure proprietary data transfer technology - so you can populate your ShareVault fast,
- Conversion to secure PDF format happens automatically with support for over 300 filetypes,
- Participants view documents in native Adobe Acrobat, locked-down with special security protocol that allows tracking of documents even after they have been downloaded, without any special document viewing software,
- Comprehensive reporting tools provide the intelligence you need to determine who has spent time reviewing the critical documents for your deal,
- 24/7/365 support hotline, with access to ShareVault experts including a remote screen-sharing capability so our techs can see the issue right on your screen,
- Bank grade solid security and reliability, with a SAS-70 type 2 certified data center, dual redundant servers, data encryption and comprehensive security protocol.
To learn more about how ShareVault can accelerate sell-side M&A due diligence, sign-up for a free demonstration.
Latest M&A News
- Are Dell’s shareholders on Xanax?
September 2nd, 2010, 07:05 AM (PDT)
Are Dell's shareholders on Xanax? The company has finally bowed out of its mad bidding war for 3PAR. Yet its investors displayed neither much concern about overpayment nor relief about the deal being dropped. After a decade of scandals, missed opportunities and dismal performance, they may have stopped caring.
- Reheating Burger King won’t be another LBO whopper
September 1st, 2010, 07:05 AM (PDT)
It's easy to see why private equity firms might salivate at the prospect of another bite at Burger King. The fast-food chain has made a fortune for a trio of buyout barons who acquired the company in 2002 and flipped it onto public markets four years later. But Burger King won't be another LBO whopper.
- HP tries big buyback to quell investor discontent
August 30th, 2010, 07:05 AM (PDT)
Sometimes an ounce of prevention is worth a pound of cure. Case in point: Hewlett-Packard. Like many tech concerns, it is sitting on a large cash pile. But the company's bidding war with Dell for control of 3PAR raises fears it may squander its $15 billion hoard on overpriced baubles. Promising to repurchase $10 billion of stock soothes investors. Refraining from such battles would be more effective.
- Sanofi, Genzyme play chicken over price
August 30th, 2010, 07:05 AM (PDT)
"Let me in and I might go higher." That in a nutshell is the message Sanofi-Aventis chief executive Chris Viehbacher is sending Genzyme's management in making public his $18.5 billion offer to buy the U.S. biotech company. The all-cash structure is intended to show that the French pharmaceuticals group is serious. But the lowball $69-a-share price has failed to move Genzyme's board. Viehbacher will be hoping that changes -- his threat of a hostile bid looks hollow for now.